A major wrongful death lawsuit has been filed alleging defects in Abbott Laboratories' (NYSE:ABT) FreeStyle Libre 3 and Libre 3 Plus glucose monitoring systems. The claim links the products to seven ...
Abbott Diabetes Care is recalling certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to falsely low glucose readings.
Check Your CGM: Recalled FreeStyle Libre 3 Sensors Associated With 7 Deaths ...
Abbott has now identified the manufacturing issue that caused the fault in the sensors used in its FreeStyle Libre 3 and Libre 3 Plus CGMs. Image credit: Jonathan Weiss via Shutterstock.com. Abbott ...
ABBOTT PARK, Ill., March 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated ...
Following a major sales bump in the second quarter of 2019, Abbott Laboratories is planning to significantly ramp up manufacturing for its FreeStyle Libre continuous glucose monitoring system, the ...
Add Yahoo as a preferred source to see more of our stories on Google. FreeStyle Libre 3 sensor by Abbott Image by Adobe Medical device giant Abbott announced on Sunday that it is recalling ...
Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation
ABBOTT PARK, Ill., Oct. 28, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre ® continuous ...
Abbott’s continuous glucose monitoring system, the FreeStyle Libre 2, has been approved in Canada for adults and children four years and older with diabetes. The FreeStyle Libre 2 system continuously ...
24/7 Wall St. on MSN
Abbott Labs just extended its dividend aristocrat status: What comes next?
Quick Read Abbott Laboratories (ABT) raised its quarterly dividend to $0.63 with a 60.4% free cash flow payout ratio.
Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding patient choice and streamlining diabetes care workflows. PALO ALTO, ...
The Freestyle Libre 14 day is now the longest-lasting self-applied continuous glucose sensing technology available and allows the used to wear the sensor for up to 14 days with high accuracy. ABBOTT ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results